Diaxonhit Mid-Year Revenues Increase to €15,9 Million

Regulatory News :

Diaxonhit (Paris:ALEHT), the leading French provider of specialty diagnostic solutions, announces consolidated mid-year revenues as of June 30, 2013 at €15.9 millions, an increase of 8.2% compared to pro forma revenues of €14.7 millions as of June 30, 2012.

Total sales of in vitro diagnostic products recorded by InGen, its commercialization affiliate, for the first semester reached €13.6 million, an increase of 10.6% compared to sales of €12.3 million recorded at mid-year 2012.

« The superior performance of our sales team during the first semester of 2013 confirms our expectations and the relevance of our acquisition of InGen last December. It also demonstrates our ability to successfully integrate both companies within a very short time-period. » said Loïc Maurel, President of Diaxonhit’s management board.

Next financial release : Half-year results for 2013, September 17, 2013

____________________

About Diaxonhit

Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully integrated leader in the in-vitro diagnostic field, involved from research to commercialization of specialty diagnostic products.

With many partnerships and a strong presence in hospitals, Diaxonhit has an extensive commercialization network. Through its affiliate, InGen, it commercializes and services, mostly under exclusivity agreements, in-vitro diagnostic kits and advanced equipment. It operates mainly in the fields of transplantation, infectious diseases and autoimmunity, product quality control and rapid tests, including Tetanus Quick Stick ®, a proprietary product. InGen is the leading supplier in France of HLA tests manufactured by Thermo-Fisher/One Lambda, of which it is the largest distributor worldwide.

The group also owns a diversified portfolio of products in development, including both innovative molecular and non-molecular diagnostics, covering three main specialty areas: immuno-infection, Alzheimer's disease and cancer.

Diaxonhit headquarters are located in Paris and its affiliate in the Paris region. The Group is listed on NYSE Alternext in Paris and is part of the NYSE Alternext OSEO innovation index.

For more information, please visit: http://www.diaxonhit.com.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, Diaxonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.